Description
Retatrutide (LY3437943) is a synthetic 39-amino acid peptide engineered from a GIP peptide backbone to act as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCGR) receptors . It incorporates non-coded amino acid residues (Aib at positions 2 and 20, αMeL at position 13) that confer stability against DPP-4 cleavage and optimise receptor activity . A C20 fatty diacid moiety enables albumin binding, resulting in a half-life of approximately 6 days and supporting once-weekly subcutaneous dosing .
This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.
Key Research Focus
Retatrutide has been investigated in preclinical and clinical research exploring its roles in:
- Triple Receptor Pharmacology: In vitro, retatrutide demonstrates 8.9-fold greater potency than human GIP at the GIP receptor, but is 2.5-fold less potent than human GLP-1 at the GLP-1 receptor and 2.9-fold less potent than human glucagon at the glucagon receptor . This distinct potency profile differentiates it from selective GLP-1 agonists and dual GIP/GLP-1 agonists.
- Weight Reduction and Metabolic Regulation: In a Phase 2 trial, retatrutide produced a mean body weight reduction of 24.2% at 48 weeks, exceeding outcomes reported for both semaglutide and tirzepatide . In the Phase 3 TRANSCEND-T2D-1 trial (n=537), retatrutide 12 mg reduced body weight by 15.3% at 40 weeks versus 2.6% with placebo . No weight loss plateau was observed through the treatment period .
- Glycaemic Control: In TRANSCEND-T2D-1, retatrutide reduced HbA1c by up to 1.94% (12 mg dose) versus 0.81% with placebo at week 40 . The proportion of participants reaching HbA1c targets of <7.0%, ≤6.5%, and <5.7% was significant for all tested doses .
- Appetite and Eating Behaviour: Pre-specified exploratory analyses from a Phase 2 study (n=275) demonstrated that retatrutide ≥4 mg produced greater reductions in overall appetite, hunger, and prospective food consumption compared to placebo at Week 24. Reductions in perceived hunger and disinhibition were significantly correlated with body weight reduction .
- Adipose Tissue Remodelling: Multi-omic profiling in preclinical models revealed that retatrutide reprogrammes epididymal white adipose tissue, characterised by suppressed lipogenesis, enhanced fatty acid oxidation, restored peroxisomal activity, and downregulated inflammatory/fibrotic pathways .
Product Specifications
- Form: Lyophilized Powder (Sterile)
- Purity: ≥95–98% (HPLC Verified)
- Molecular Weight: ~4731 Da (as peptide backbone with C20 diacid moiety)
- Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
- Solubility: Soluble in sterile water or buffer for laboratory use.
- Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.
Why Choose Retatrutide?
Retatrutide offers a mechanistically distinct research tool for studying simultaneous activation of three complementary metabolic hormone pathways. Unlike GLP-1 monoagonists or GIP/GLP-1 dual agonists, the addition of glucagon receptor targeting may enhance energy expenditure and fat metabolism while maintaining glycaemic control . Its well-characterised receptor potency profile, extensive Phase 2 and Phase 3 clinical data demonstrating unprecedented weight reduction, and ongoing development across multiple metabolic indications make it a valuable reagent for metabolic and obesity research.




